The CRISPR/Cas9 system, known for its programmability and specificity in gene editing, faces challenges due to structural and stability alterations in the genome. The transition from Cas9 to dCas9, lacking endonuclease activity but retaining DNA binding ability, has paved the way for the development of CRISPRa and CRISPRi tools. These tools, by modifying chromosomal elements, regulate gene transcription, impacting gene function, high-throughput screening, and disease treatment. CRISPR technology, with its diverse types and subtypes, has revolutionized gene editing, particularly with the widely used CRISPR/Cas9 system.
CRISPR/Cas9-mediated gene knock-out or knock-in relies on Cas9’s endonuclease activity and subsequent repair mechanisms. The CRISPR/dCas9 system, by linking effector proteins, offers a non-invasive method to regulate gene expression through epigenetic modifications. The dCas9-KRAB fusion protein is a prominent tool for gene suppression, showcasing potential in gene function research, disease treatments, and regulatory element screening. Additionally, the dCas9-DNMT3A fusion protein induces DNA methylation, while dCas9-HDAC8 regulates histone deacetylation, both playing crucial roles in gene regulation and disease exploration.
CRISPRi tools, like dCas9-KRAB, provide short-term gene expression suppression, offering insights into gene function and regulatory element screening. On the other hand, CRISPRa tools, such as dCas9-VP64 and dCas9-p300, activate gene expression by catalyzing histone modifications, opening avenues for treating various diseases. The CRISPR/dCas9 system, though efficient, faces challenges such as off-target effects, cytotoxicity, and vector delivery issues. Novel delivery systems and advancements in effector fusion proteins aim to enhance the CRISPR/dCas9 system’s specificity and efficiency.
The CRISPR/dCas9 system presents a promising approach to precisely regulate gene expression through epigenetic modifications, minimizing risks associated with genome editing. By leveraging the tools like dCas9-KRAB, dCas9-DNMT3A, and dCas9-p300, researchers can delve into gene function, disease mechanisms, and potential therapeutic targets. Overcoming challenges such as delivery methods and efficiency of effectors will further broaden the application of CRISPR/dCas9 technology in gene therapy and precision medicine, offering a safer and more targeted approach to gene regulation.
Tags: regulatory, gene therapy, upstream
Read more on pmc.ncbi.nlm.nih.gov